HANGZHOU and SHAOXING, China, May 4, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) today announces the positive Phase IIa clinical results of ASC22 (Envafolimab), which is a first-in-class, subcutaneously administered PD-L1 antibody for chronic hepatitis B (CHB) functional cure....
from PR Newswire: https://ift.tt/3xKESD5
No comments:
Post a Comment